Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has signed a production agreement with Tergus Pharma for GLP and GMP materials related to its cancer treatment drug, HT-001. This follows their request for a Pre-Investigational New Drug meeting with the FDA regarding HT-001, which targets skin disorders associated with EGFR inhibitor therapy. Hoth aims to alleviate dose-limiting skin toxicities, thus enhancing patient outcomes in cancer treatments. CEO Robb Knie expressed optimism for the drug's development and its potential to benefit patients.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has requested a Pre-Investigational New Drug (IND) meeting with the FDA regarding HT-001, a topical treatment aimed at addressing skin disorders from epidermal growth factor receptor (EGFR) inhibitor therapy. Over 50% of cancer patients on EGFR inhibitors experience dermatological side effects, impacting their treatment. HT-001 seeks to improve these patients' quality of life. Currently in preclinical development, the company plans to discuss clinical trial designs in its upcoming FDA meeting scheduled for Q1 2021.

Hoth (NASDAQ: HOTH) has partnered with Zylö Therapeutics to co-develop a topical treatment for Cutaneous Lupus Erythematosus (CLE), utilizing a patented delivery system called Z-pods™. The drug HT-005, targeting the endocannabinoid pathway, showed proof-of-concept efficacy in reducing skin plaques during a study in MRL/MpJ-Faslpr/J mice. This collaboration aims to address the limited therapeutic options available for CLE, which significantly impacts patient quality of life.

Hoth Therapeutics (NASDAQ: HOTH) has secured Human Research Ethics Committee (HREC) clearance to initiate its Phase 1b clinical trial of BioLexa Lotion for treating mild to moderate atopic dermatitis in Australia. Dosing of the first subject is expected early 2021, with top-line data anticipated in Q1 2021. The trial aims to evaluate the safety and pharmacokinetics of BioLexa, with preliminary efficacy assessed in a second patient cohort. CEO Robb Knie emphasized the milestone as crucial for submitting data for future FDA considerations.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced promising preclinical data for its therapy HT-005 targeting Cutaneous Lupus Erythematosus (CLE). Conducted by Jackson Laboratory with Zylö Therapeutics, results showed a significant reduction in skin plaque severity in mice after using HT-005-loaded topical Z-pods™. Improvements were observed within 3 weeks and maintained through 10 weeks. CEO Robb Knie expressed optimism about the therapeutic's potential addressing a high unmet need in CLE.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced key milestones in its COVID-19 product development. The company is progressing with its HT-002 peptide therapeutic aimed at treating COVID-19 symptoms, with inhibition test data expected in December 2020. The On-the-Go SARS-CoV-2 Testing Device is in research, aiming for proof-of-concept data by year-end 2020. Additionally, the VaxCelerate vaccine platform shows promise in animal models, with further preclinical studies planned. Hoth is focused on rapid development to address critical medical needs in COVID-19.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the granting of U.S. Patent No. 10,793,525 for novel 13-Cis-RAMBA retinamides aimed at targeting cancer-associated signaling pathways. This first-of-its-kind patent expires on October 5, 2036. The compounds are designed to disrupt the MNK1/2-driven signaling pathway linked to various cancers, including breast and prostate cancer. Hoth's CEO, Robb Knie, emphasized the patent's contribution to their diverse intellectual property portfolio, which supports continued development in oncology and dermatology therapeutics.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) reported progress on its HT-003 acne treatment, demonstrating the ability to inhibit toll-like receptor 2 (TLR2) gene expression in human keratinocytes, crucial for acne pathophysiology. The research led by Dr. Jonathan Zippin showed no toxicity at doses up to 50 µM. Future testing will focus on determining the minimal effective dose and studying HT-003's broader applications for inflammatory diseases. Hoth aims to enhance life quality for patients with dermatological disorders through innovative therapies.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has entered a Sponsored Research Agreement with George Washington University to develop a rapid diagnostic device for SARS-CoV-2. This mobile testing solution aims to provide immediate COVID-19 test results using a plasmonic system, allowing patients to detect the virus anywhere. The device has potential for significant public health impact by streamlining testing processes. Initial discussions with the FDA regarding emergency use authorization are planned for early 2021.